Printer Friendly

HIV-AIDS Industry Report Features Aethlon Medical.

Business Editors/Health & Medical Writers

LA JOLLA, Calif.--(BW HealthWire)--July 10, 2001

Aethlon Medical (OTCBB:AEMD) announced today that the Company's HIV-Hemopurifier(TM) has been featured within an HIV/AIDS Industry Report entitled "Major Developments in the Treatment of HIV/AIDS." The 50-page report, published by Griffin Securities, Inc., provides in-depth market analysis, including reviews of current HIV/AIDS treatments and promising new treatments, such as the HIV-Hemopurifier(TM) from Aethlon Medical.

Included among the references to Aethlon Medical, the report states: "Researchers from Aethlon Medical have developed a promising extracorporeal entry inhibitor, the HIV-Hemopurifier(TM) (HIV dialysis). Recent preclinical studies of the HIV-Hemopurifier(TM), utilized with a standard dialysis machine, has shown removal of 90% of HIV from human blood plasma during the equivalent of one overnight treatment.

"The HIV-Hemopurifier, by decreasing viral load, appears to have a number of attributes necessary for a globally practical therapy for HIV, both as a conjunctive and salvage therapy. And by removing mutant strains, could extend the life of currently approved drugs and could represent a valuable lifecycle management strategy.

"Also, since the HIV-Hemopurifier(TM) does not cause cross-resistance, and given the new government guidelines that encourage the delay of initial drug regimens, it may be utilized as a first line therapy, reducing viral load, delaying the need to start antiviral therapy. Aethlon Medical's (OTC:AEMD) dialysis approach could also represent an important adjunct therapy for current dialysis patients that are co-infected with HIV (estimated to be a significant percent of the current kidney dialysis population)."

Other companies featured in the report include: DuPont (DD), Bristol Myers Squibb (BMY), Triangle Pharmaceuticals (VIRS), Pfizer (PFE), Merck (MRK), Abbott Laboratories (ABT), GlaxoSmithKline (GSK), Trimeris (TRMS), Progenics Pharmaceuticals, Inc. (PGNX), Schering-Plough (SGP), Chiron Corporation (CHIR), Hollis-Eden Pharmaceuticals (HEPH), Cel-Sci (CVM), VaxGen (VXGN), Immune Response (IMNR), Targeted Genetics (TGEN), and Aventis Pasteur (AVE).

Griffin Securities, Inc. (member NASD and SIPC) based in New York City is a subsidiary of the publicly traded Cater Barnard Plc. based in the U.K. Griffin serves corporations, institutions and individuals worldwide with a diverse range of financial services including private capital markets; mergers & acquisitions; financial advisory; brokerage and research. Griffin Securities Chief Investment Officer, Ms. Chrystyna Bedrij, is a regular columnist for msnbc.com and has been a respected Wall Street analyst for over ten years.

Aethlon Medical is a development stage therapeutic company focused on expanding the applications of its Hemopurifier platform technology which rapidly reduces the presence of viruses and other intoxicants in the blood. Aethlon's lead product candidate, the HIV-Hemopurifier(TM) is designed to fill the urgent need for new HIV/AIDS treatments that are effective in reducing viral load, have fewer side effects, and decrease the likelihood of treatment resistance. The product is initially targeted as a "Salvage Therapy" for the growing population of HIV-infected, who as a result of resistance to available AIDS drugs, are left without any effective treatment options. Aethlon also plans to position the HIV-Hemopurifier(TM) as a primary treatment for those waiting to initiate treatment with anti-HIV drugs as advised under new federal guidelines, and as a conjunctive therapy to enhance and extend the performance of established pharmaceutical regimens.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. (the "Company"), or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Readers of this press release may obtain additional information on the Company in reports and other information filed in accordance with the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Such reports and other information filed by the Company can be inspected and copied at the public reference facilities maintained by the Commission at the Public Reference Room, 450 Fifth Street, N.W., Washington, DC 20549. Copies of such material can also be obtained at prescribed rates from the Public Reference Section of the Commission, Washington, DC 20549 or by calling the Commission at 1-800-SEC-0330. In addition, Registration Statements and other filings made with the Commission through its Electronic Data Gathering Analysis and Retrieval System ("EDGAR") and publicly available through the Commission's website located at http://www.sec.gov.
COPYRIGHT 2001 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2001, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Jul 10, 2001
Words:727
Previous Article:TANDBERG Pioneers Industry's Most Advanced Software for Videoconferencing Systems.
Next Article:Insmed Added To Russell 3000 and Russell 2000 Indexes.
Topics:


Related Articles
United Press International Publishes Science Feature On Aethlon Medical's AIDS Treatment.
Aethlon Medical Appoints James A. Joyce as President and CEO, and Announces Private Placement of Stock.
American Clinical Laboratory Magazine Publishes Article on Aethlon Medical AIDS Treatment.
INDIA AND CII SUPPORT AETHLON HIV/HEPATITIS TRIALS.
HIV travel restrictions: where to find help navigating them.
Medicare HIV fact sheet: caution re January 2006.
AETHLON MEDICAL LAUNCHES HEPATITIS-C CLINICAL TRIAL.
Emerging pediatric HIV epidemic related to migration.
Contest for best video game concept against AIDS, deadline March 16.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters